Virios Therapeutics Inc. (NASDAQ: VIRI) Stock Information | RedChip

Virios Therapeutics Inc. (NASDAQ: VIRI) Listen to this Section


$0.18
+0.0043 ( +2.45% ) 170.9K

Virios Therapeutics Inc is a development-stage biotechnology company. It is focused advancing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response, such as fibromyalgia ("FM") and Long-COVID ("LC"). Its product candidates includes IMC-1 and IMC-2, IMC-1, is intended to synergistically suppress herpesvirus activation and replication with a more specific activity against the Epstein-Barr virus (herpesvirus HHV-4, IMC-2 is a combination of valacyclovir and celecoxib.

Market Data


Open


$0.18

Previous close


$0.18

Volume


170.9K

Market cap


$5.24M

Day range


$0.18 - $0.19

52 week range


$0.16 - $1.37

Insider Ownership Transactions

Total Amount Purchased: -375,775.00 | $ -67,564.35

Date Type Amount Purchased Purchaser
2024-02-28 Sale -2917.00 Pridgen William
2024-02-28 Sale -4000.00 Whitley Richard James
2024-02-28 Sale -4709.00 Keefer David R
2024-02-28 Sale -2917.00 Burch Richard Alan
2024-02-28 Sale -3959.00 De La Rosa Abel
2024-02-28 Sale -63618.00 Walsh Angela
2024-02-28 Sale -62568.00 Grosswald Ralph
2024-02-28 Sale -88085.00 Gendreau Roger Michael
2024-02-28 Sale -138835.00 Duncan Gregory Scott
2024-02-28 Sale -4167.00 Thomas John C

SEC Fillings


Form Type Description Pages Date
10-q Quarterly Reports 52 Aug 09, 2024
8-k 8K-related 15 Aug 08, 2024
8-k 8K-related 13 Jun 20, 2024
8-k 8K-related 13 Jun 12, 2024
8-k 8K-related 74 May 20, 2024
10-q Quarterly Reports 52 May 10, 2024
8-k 8K-related 15 May 09, 2024
8-k 8K-related 13 May 07, 2024
ars Annual reports 1 Apr 29, 2024
def Proxies and info statements 4 Apr 25, 2024

Latest News


Terms and Agreement

Please agree to the terms to continue using the chat feature.